Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

Carneiro, B. A., Papadopoulos, K. P., Strickler, J. H., Lassman, A. B., Waqar, S. N., Chae, Y. K., Patel, J. D., Shacham-Shmueli, E., Kelly, K., Khasraw, M., Bestvina, C. M., Merrell, R., Huang, K., Atluri, H., Ansell, P., Li, R., Jin, J., Anderson, M. G., Reilly, E. B., … Gan, H. K. (2022). Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdac183
Authors:
Benedito A Carneiro
Kyriakos P Papadopoulos
John H Strickler
Andrew B Lassman
Saiama N Waqar
Young Kwang Chae
Jyoti D Patel
Einat Shacham-Shmueli
Karen Kelly
Mustafa Khasraw
Christine M Bestvina
Ryan Merrell
Kevin Huang
Harisha Atluri
Peter Ansell
Rachel Li
Janet Jin
Mark G Anderson
Edward B Reilly
Gladys Morrison-Thiele
Kalpesh Patel
Randy R Robinson
Martha R Neagu Aristide
Hui K Gan
Affiliated Authors:
Andrew B Lassman
Author Keywords:
antibody-drug conjugate
egfr
glioblastoma
phase i
serclutamab talirine
Publication Type:
Article
Unique ID:
10.1093/noajnl/vdac183
PMID:
Publication Date:
Data Source:
PubMed

Record Created: